TRex Bio prices $117M IPO to support immune drug work
TRex Bio priced its IPO at $117M, selling 8.3M shares at $14 each, and will trade on Nasdaq under 'TRXB'. The company is developing immune drugs, with TRB-061 in Phase 1 trials and TRB-071 planned for testing. Eli Lilly, its largest shareholder, may also buy IPO shares. TRex has raised $220M in venture financing. Another biotech, Retension Pharmaceuticals, also went public with a $45M offering, highlighting increased biotech IPO activity in 2026.
How this was made
The 30-second read
Why it matters
The $117M raise provides runway for Phase 1 trials and positions the company among a growing cohort of 2026 biotech IPOs.
Market read
First‑day trading of TRXB will attract biotech‑focused investors and may set tone for upcoming biotech listings.
What to watch
Potential dilution from future secondary offerings and the need for successful trial data to sustain price.
Background
TRex Bio is a newly formed immune‑modulating biotech raising capital to advance its Treg‑focused pipeline.
Market effects
Adds to the pipeline of 2026 biotech IPOs, indicating continued capital appetite for immune‑targeted therapies.
Boosts Nasdaq biotech listings, modestly supporting US biotech sector sentiment.
Limited to biotech investors; no broader macro effect.
Counterpoint
If demand for biotech IPOs wanes, the stock could face immediate sell‑off after the initial pop.
Key entities
- companyTRex Bio
Immune‑modulating biotech launching IPO.
- investorEli Lilly
Largest equity holder of TRex Bio, holding ~24% pre‑IPO.
- partnerJohnson & Johnson
Partnering with TRex Bio on anti‑inflammatory drug development.
